Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors For the past 25 years, TIME’s Best ...

TIME names NanoKnife one of 2025’s Best Inventions — already treating prostate cancer in Toronto with precise, function-preserving results. TIME's recognition of NanoKnife (IRE) reinforces what we’ve ...

He was diagnosed with prostate cancer but his insurance company felt the treatment was 'unproven' - despite his 'no limit' ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

AngioDynamics CEO James Clemmers speaks to investors about FDA approval for the company’s NanoKnife. Time magazine named NanoKnife one of the best inventions of 2025. COLONIE — It was not even a year ...

AngioDynamics ANGO recently announced expanded indications in Europe for its NanoKnife System, broadening its clinical utility in soft tissue tumor ablation. The expanded approval covers NanoKnife’s ...